Exposure to LHRH agonists in early pregnancy following the commencement of mid-luteal buserelin for IVF stimulation.
Exposure to buserelin in early pregnancy has been reported following its use in in-vitro fertilization treatment cycles. The number of reported cases is small. There are still no answers regarding embryotoxicity, and the need for luteal support is still unclear. A further six cases are reported here, five receiving luteal support and resulting in the delivery of healthy children, and one, without luteal support ending in a first trimester miscarriage. We propose that further data should be collected to allow adequate monitoring and follow-up of these pregnancies.
Jackson
A E
AE
Academic Department of Obstetrics and Gynaecology, Royal Free Hospital, London, UK.
Curtis
P
P
Amso
N
N
Shaw
R W
RW
D000022:Abortion, Spontaneous / Q000139:chemically induced; D000281:Administration, Intranasal; D000328:Adult; D002064:Buserelin / Q000009:adverse effects* / Q000627:therapeutic use; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D008183:Luteal Phase; D010062:Ovulation Induction; D011247:Pregnancy; D011256:Pregnancy Outcome; D011261:Pregnancy Trimester, First; D011374:Progesterone / Q000627:therapeutic use
D006063:Chorionic Gonadotropin; D011374:Progesterone; D002064:Buserelin